Table 2. Descriptive univariate analysis of explanatory factors predicting time to tumour progression for patients treated with octreotide.
|
Cox regression |
||||||
|---|---|---|---|---|---|---|
| Explanatory factor | Levels | Sample size | Progression events | KM median months to progression (95% CI) | Coefficient | P-values |
| Age | ⩽60 | 115 | 64 | 43 (32, 71) | NA | NA |
| >60 | 139 | 66 | 33 (28, 65) | 0.04 | 0.84 | |
| Sex | Female | 120 | 72 | 32 (23, 45) | NA | NA |
| Male | 134 | 58 | 49 (36, 96) | −0.42 | 0.02 | |
| Reason for treatment | Functional | 145 | 83 | 32 (27, 51) | NA | NA |
| Functional & progression | 8 | 4 | 43 (21, NA) | −0.23 | 0.65 | |
| Functional & PROMID | 21 | 10 | 30 (19, NA) | 0.17 | 0.62 | |
| Progression | 24 | 11 | 50 (35, NA) | −0.56 | 0.10 | |
| PROMID | 47 | 17 | 53 (28, NA) | −0.25 | 0.35 | |
| Primary tumour | Small bowel | 204 | 101 | 43 (32, 64) | NA | NA |
| Pancreas | 22 | 17 | 20 (12, 79) | 0.52 | 0.058 | |
| Lung | 14 | 6 | NA (11, NA) | 0.37 | 0.38 | |
| Rectum | 7 | 4 | 8 (4, NA) | 1.4 | 0.062 | |
| Volume liver metastases | 0 | 51 | 16 | 105 (36, NA) | NA | NA |
| 1 | 79 | 39 | 37 (26, 79) | 0.63 | 0.036 | |
| 2 | 37 | 20 | 23 (13, NA) | 0.88 | 0.0089 | |
| 3 | 26 | 15 | 33 (20, NA) | 0.87 | 0.016 | |
| Skeletal metastases | No | 221 | 110 | 40 (33, 60) | NA | NA |
| Yes | 32 | 19 | 20 (16, NA) | 0.51 | 0.043 | |
| Peritoneal metastases | No | 176 | 87 | 46 (30, 71) | NA | NA |
| Yes | 78 | 43 | 33 (30, 45) | 0.28 | 0.14 | |
| Mesenteric metastases | No | 209 | 109 | 37 (31, 64) | NA | NA |
| Yes | 43 | 19 | 32 (22, NA) | −0.043 | 0.86 | |
| Carcinoid heart | No | 229 | 119 | 36 (30, 51) | NA | NA |
| Yes | 24 | 10 | 72 (33, NA) | −0.58 | 0.082 | |
| Grade | 1 (low) | 148 | 71 | 45 (33, 72) | NA | NA |
| 2 (intermediate) | 59 | 37 | 21 (15, 37) | 0.73 | <0.001 | |
| Functional | No | 183 | 92 | 45 (31, 65) | NA | NA |
| Yes | 67 | 34 | 36 (26, NA) | −0.027 | 0.89 | |
| Desmoplasia | No | 185 | 96 | 36 (30, 64) | NA | NA |
| Yes | 67 | 32 | 36 (30, NA) | −0.14 | 0.5 | |
| Tumour resected | No | 134 | 72 | 36 (30, NA) | NA | NA |
| Yes | 117 | 55 | 43 (30, 78) | −0.17 | 0.36 | |
| Chromogranin A | <60 (normal) | 29 | 10 | 93 (35, NA) | NA | NA |
| 61–600 (elevated) | 98 | 42 | 53 (19, 79) | 0.59 | 0.097 | |
| >600 (very elevated) | 35 | 22 | 30 (19, NA) | 1.15 | 0.0029 | |
Abbreviations: CI=confidence interval; KM=Kaplan–Meier; NA=not available.
For the Cox regression results: (a) coefficients are negative for a slower time to tumour progression (a better response) and vice versa, and (b) baseline factor levels are not associated with a coefficient or P-value and are denoted NA. Some upper confidence limits for the KM estimate of the median time to progression could not be estimated from the available data and are denoted NA. The median time to progression of bronchial primary tumours could also not be estimated from the available data.